Eli Lilly (LLY): FY24 Q3 earnings call, Oct 30, 2024
No Kalshi or Polymarket word markets were listed for Eli Lilly’s Oct 30, 2024 earnings call (FY24 Q3). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
19 matches for “Phase 3”; 5 quoted, at least 25 words apart.
…early symptomatic Alzheimer's disease. Disclosure of positive 176-week data from the SURMOUNT-1 Phase 3 study of tirzepatide in adults with pre-diabetes and obesity or overweight.…
…So let me begin by sharing some late-phase updates, including some exciting Phase 3 data that we shared at recent medical congresses. Starting with neuroscience.…
…Our efforts on Remternetug continue to progress and we are starting a Phase 3 efficacy study of Remternetug focused on preclinical phase of the disease.…
…Turning to Cardiometabolic Health. Last month we shared data from our remaining Phase 3 studies for our weekly basal insulin called Insulin efsitora alfa. As…
…first time. We look forward to discussing the results from the QWINT Phase 3 program with global regulatory agencies. It has also been a productive…
Agents: this page as TSV at /api/v1/appearances/eli-lilly:2024-10-30:earnings_call · words: /api/v1/brief?appearance=eli-lilly:2024-10-30:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP